Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: kidney
- Who it enrolls
- age 18 Years to 84 Years; no BMI minimum stated; conditions: Chronic Kidney Disease; Type 2 Diabetes
- Interventions
- Finerenone; Semaglutide; Lotensin; Capoten; Enalapril; Monopril; Lisinopril; Univasc; Aceon; Accupril; Altace; Mavik; Edarbi; Atacand; Avapro; Cozaar; Benicar; Micardis; Diovan; Invokana; Farxiga; Jardiance; Ertugliflozin; Brenzavvy; Sotagliflozin
- Conditions
- Chronic Kidney Disease; Type 2 Diabetes
- Phase and size
- Phase 4 · 64 participants
- Dates
- Start 2026-04-30
Primary completion 2029-03-31 - Sponsor
- Baylor Research Institute (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- On-study retention rate at 6 months6 months
- Sustained decline in eGFR ≥30%6 months
- Change in UACR6 months
02Eligibility
Who can take part
Inclusion Criteria: * Patients aged 18-84 years * eGFR 45 to ≤90 mL/min/1.73 m2 * UACR \>200 mg/g * diagnosis of T2D * receiving ≤2 guideline-recommended drug classes irrespective of dose for ≥4 weeks prior to screening * eligible for all 4 drugs * systolic BP (SBP) \>90 mmHg * those willing to provide written informed consent and to adhere to study visits. Exclusion Criteria: * Type 1 diabetes * any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.) * history of kidney transplant * liver disease (i.e., aspartate transaminase or alanine transaminase \>5 times, or bilirubin \>3 times the upper limit of normal) * serum potassium \>5.5 mEq/L at baseline * known hypersensitivity to any study drug * life expectancy \<6 months * active malignancy or infection * brittle diabetes (defined as severe glycemic instability with hospitalization or emergency care for hypoglycemia or hyperglycemia within the past 6 months) * high-risk of hypoglycemia (Clarke or Gold score ≥4) * predicted 12-month risk of hypoglycemia related emergency visits or hospitalizations \>5% using the Kaiser Permanente hypoglycemia prediction score * high dose insulin use (\>1 unit/kg/day). * RASi: hyperkalemia or angioedema * SGLT2i: diabetic ketoacidosis, type 1 diabetes, recurrent genitourinary infections * ns-MRA: hyperkalemia * GLP1-RA: personal or family history of medullary thyroid carcinoma, known gastroparesis, or pancreatitis.
03Change log
Registry changes
No changes recorded since the trial was added.